A crackdown on corruption and pricing in China's fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over. A Reuters' analysis of more than 60 listed Chinese healthcare firms shows average profit margins declined to around 10 percent last year from 15 percent in 2012. China has been a magnet for the big global pharmaceutical companies and other healthcare firms as growth slows in Europe and the United States. While global drugmakers withhold their China profit figures, the analysis suggests profit growth is harder to come by - a concern as many global firms look to China as a future growth driver.
via Business News - Yahoo Finance http://ift.tt/1t7ZqMl
0 commentaires:
Enregistrer un commentaire